

Board and Executive Leadership Update

Melbourne, Australia – 21 March 2025: Leading digital health company [Adherium Limited](#) (ASX:ADR), provides the following update regarding changes to its Board and executive leadership team.

Intended Appointment of Non-Executive Director – Mr. Keven Gessner

The Company is pleased to announce its intention to appoint Mr. Keven Gessner as a Non-Executive Director of Adherium. The proposed appointment is subject to Mr. Gessner satisfying all applicable regulatory requirements under the Corporations Act 2001 (Cth), including obtaining a Director Identification Number (DIN) prior to his formal appointment.

Mr. Gessner is a senior executive with over 25 years of experience in the pharmaceutical and digital health sectors. His career includes leadership roles at Pfizer, Teva, AstraZeneca, and GlaxoSmithKline (GSK). He has served as Vice President of Pricing and Contracting at Pfizer and led Digital Health and Respiratory brand teams for Teva and AstraZeneca's US respiratory commercial businesses.

Mr. Gessner brings extensive expertise in digital health, market access, product launch strategy, and brand marketing across therapeutic areas including respiratory, cardiovascular, diabetes, and vaccines. He has a proven track record of leading successful product launches and commercial strategies, including the launch of the first fully integrated respiratory drugs with built-in electronics to remotely monitor patients with COPD and asthma for Teva. Additionally, he has spearheaded initiatives leveraging AI and machine learning to predict health outcomes based on data from digital respiratory therapies.

The Board looks forward to the value Mr. Gessner's experience and expertise will bring to Adherium as it expands its digital health solutions and remote patient monitoring capabilities. An update will be provided once his appointment becomes effective.

Intended Resignation of Non-Executive Director – Mr. William Hunter

Adherium also advises that Dr William Hunter will be stepping down from the Board as an Independent Non-Executive Director, effective at the same time of Mr Keven Gessner's appointment. Dr Hunter was appointed to the Adherium Board on 17 December 2015 and has brought invaluable experience in the commercialisation of medical device technologies throughout his tenure.

Mr Lou Panaccio, Adherium Independent Non-Executive Chair, commented: *"On behalf of the Board and the entire Adherium team, I would like to extend our sincere gratitude to Dr Hunter for his extraordinary contributions over the past nine years. His strategic insights and deep sector expertise have played an instrumental role in Adherium's growth and development."*

Resignation of Chief Financial Officer – Daniel Kaplon

Adherium also advises that Mr. Daniel Kaplon has notified the Board of his decision to resign as Chief Financial Officer (CFO) of the Company. Mr. Kaplon will remain in his role to assist with an orderly transition, with his departure effective 31 May 2025.

Mr Jeremy Curnock Cook, Acting Chief Executive Officer, commented, *"I would like to thank Daniel on behalf of Adherium and our entire team for his professionalism and contribution. During this period, Daniel helped the company through a important transformational stages and key fund-raising rounds. I appreciate Daniel's support and wish him all the best."*

A search process has commenced to identify a new CFO, and the Company will provide further updates in due course.

[Learn more at adherium.com](https://www.adherium.com)

- ENDS -

This ASX announcement was approved and authorised for release by the Board

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK Director
haley@hck.digital

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. **Learn more at [adherium.com](https://www.adherium.com)**